Gilead Sciences, Inc. (NASDAQ: GILD) has a higher price-to-earnings ratio of 103.39x compared to its average ratio. GILD has 36-month beta value of 0.20. Analysts have mixed views on the stock, with 11 analysts rating it as a “buy,” 2 as “overweight,” 15 as “hold,” and 0 as “sell.”
The public float for GILD is 1.24B, and currently, short sellers hold a 1.61% ratio of that float. The average trading volume of GILD on October 07, 2024 was 6.55M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
GILD) stock’s latest price update
The stock of Gilead Sciences, Inc. (NASDAQ: GILD) has increased by 0.50 when compared to last closing price of 84.17. Despite this, the company has experienced a 1.17% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-10-05 that Gilead’s lenacapavir may become a blockbuster HIV prophylactic. Biktarvy maintains a dominant market share in the HIV treatment space, contributing significantly to Gilead’s revenue growth. Gilead’s oncology segment is expanding, with Trodelvy and Yescarta showing potential for accelerated revenue growth.
GILD’s Market Performance
Gilead Sciences, Inc. (GILD) has experienced a 1.17% rise in stock performance for the past week, with a 7.39% rise in the past month, and a 25.23% rise in the past quarter. The volatility ratio for the week is 1.56%, and the volatility levels for the past 30 days are at 1.79% for GILD. The simple moving average for the past 20 days is 2.07% for GILD’s stock, with a 14.70% simple moving average for the past 200 days.
Analysts’ Opinion of GILD
Many brokerage firms have already submitted their reports for GILD stocks, with Raymond James repeating the rating for GILD by listing it as a “Outperform.” The predicted price for GILD in the upcoming period, according to Raymond James is $93 based on the research report published on July 08, 2024 of the current year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see GILD reach a price target of $85, previously predicting the price at $90. The rating they have provided for GILD stocks is “Buy” according to the report published on May 01st, 2024.
HSBC Securities gave a rating of “Hold” to GILD, setting the target price at $69 in the report published on April 24th of the current year.
GILD Trading at 7.26% from the 50-Day Moving Average
After a stumble in the market that brought GILD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.73% of loss for the given period.
Volatility was left at 1.79%, however, over the last 30 days, the volatility rate increased by 1.56%, as shares surge +7.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.56% upper at present.
During the last 5 trading sessions, GILD rose by +1.17%, which changed the moving average for the period of 200-days by +6.40% in comparison to the 20-day moving average, which settled at $83.17. In addition, Gilead Sciences, Inc. saw 4.42% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GILD starting from Parsey Merdad, who sale 2,000 shares at the price of $83.83 back on Oct 01 ’24. After this action, Parsey Merdad now owns 100,189 shares of Gilead Sciences, Inc., valued at $167,660 using the latest closing price.
MERDAD V PARSEY, the Officer of Gilead Sciences, Inc., proposed sale 2,000 shares at $83.83 during a trade that took place back on Oct 01 ’24, which means that MERDAD V PARSEY is holding shares at $167,660 based on the most recent closing price.
Stock Fundamentals for GILD
Current profitability levels for the company are sitting at:
- 0.36 for the present operating margin
- 0.78 for the gross margin
The net margin for Gilead Sciences, Inc. stands at 0.04. The total capital return value is set at 0.24. Equity return is now at value 5.34, with 1.82 for asset returns.
Based on Gilead Sciences, Inc. (GILD), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at 0.32. The debt to equity ratio resting at 1.28. The interest coverage ratio of the stock is 10.38.
Currently, EBITDA for the company is 11.7 billion with net debt to EBITDA at 1.69. When we switch over and look at the enterprise to sales, we see a ratio of 4.53. The receivables turnover for the company is 5.96for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.14.
Conclusion
To put it simply, Gilead Sciences, Inc. (GILD) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
